The positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate.
Inspection Record
Valeo Pharma Inc — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
Investigations into deviations, reports, and/or follow-up actions were inadequate.
The system for reviewing, revising, and approving standard operating procedures was inadequate. Documents were not available in one of the official languages.
The written agreement for outsourcing fabrication, packaging or labelling, and/or testing activities was inadequate.
The content of the batch certificate was inadequate. The availability or the content of the authentic certificate of analysis was inadequate.
The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.
The quality control department's handling of complaints and/or information received about drug quality was inadequate.
The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
The written procedures for recalls were inadequate.
About this record
Extracted automatically from the document of the Health Canada inspection on 2021-12-13. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
